Cardio Diagnostics Holdings Stock Today
| CDIO Stock | USD 0.30 0 0.33% |
Performance0 of 100
| Odds Of DistressOver 56
|
Cardio Diagnostics is selling at 0.301 as of the 28th of November 2024; that is 0.33 percent increase since the beginning of the trading day. The stock's open price was 0.3. Cardio Diagnostics has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Cardio Diagnostics Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of September 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of January 2022 | Category Healthcare | Classification Health Care |
Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of cardiovascular disease. Cardio Diagnostics Inc. was founded in 2017 and is based in Chicago, Illinois. Cardio Diagnostics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 40.44 M outstanding shares of which 1.68 M shares are currently shorted by private and institutional investors with about 0.7 trading days to cover. More on Cardio Diagnostics Holdings
Moving together with Cardio Stock
Moving against Cardio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cardio Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Cardio Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cardio Diagnostics' financial leverage. It provides some insight into what part of Cardio Diagnostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cardio Diagnostics Holdings (CDIO) is traded on NASDAQ Exchange in USA. It is located in 311 West Superior Street, Chicago, IL, United States, 60654 and employs 7 people. Cardio Diagnostics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.58 M. Cardio Diagnostics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 40.44 M outstanding shares of which 1.68 M shares are currently shorted by private and institutional investors with about 0.7 trading days to cover.
Cardio Diagnostics Holdings currently holds about 9.66 M in cash with (5.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cardio Diagnostics Probability Of Bankruptcy
Ownership AllocationCardio Diagnostics Holdings shows 9.86 percent of its outstanding shares held by insiders and 4.14 percent owned by other corporate entities.
Check Cardio Ownership Details
Cardio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jones Financial Companies Lllp | 2024-06-30 | 6 K | |
| Tower Research Capital Llc | 2024-06-30 | 5.7 K | |
| Wolverine Asset Management Llc | 2024-09-30 | 3.8 K | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 3.1 K | |
| Bank Of America Corp | 2024-06-30 | 151 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Vontobel Holding Ltd. | 2024-06-30 | 0.0 | |
| Blackrock Inc | 2024-06-30 | 1.1 M | |
| Vanguard Group Inc | 2024-09-30 | 232.1 K | |
| Geode Capital Management, Llc | 2024-09-30 | 184.4 K | |
| Ubs Group Ag | 2024-06-30 | 90.9 K |
Cardio Diagnostics Historical Income Statement
Cardio Stock Against Markets
Cardio Diagnostics Corporate Management
| Esq JD | Chief Officer | Profile | |
| Timur Dogan | Chief Officer | Profile | |
| Meeshanthini Dogan | CEO CoFounder | Profile | |
| Khullani JD | Vice Strategy | Profile | |
| MBA JD | CFO Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardio Diagnostics. If investors know Cardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardio Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Revenue Per Share 0.002 | Quarterly Revenue Growth 3.562 | Return On Assets (0.98) | Return On Equity (2.93) |
The market value of Cardio Diagnostics is measured differently than its book value, which is the value of Cardio that is recorded on the company's balance sheet. Investors also form their own opinion of Cardio Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Cardio Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardio Diagnostics' market value can be influenced by many factors that don't directly affect Cardio Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardio Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardio Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.